TWENTY ONE CAPITAL INC-CL A (XXI) Fundamental Analysis & Valuation

NYSE:XXI • US90138L1098

Current stock price

6.22 USD
-0.17 (-2.66%)
Last:

This XXI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. XXI Profitability Analysis

1.1 Basic Checks

  • In the past year XXI was profitable.
XXI Yearly Net Income VS EBIT VS OCF VS FCFXXI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 1M 2M 3M

1.2 Ratios

  • With a Return On Assets value of 2.87%, XXI perfoms like the industry average, outperforming 52.30% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 2.93%, XXI is doing worse than 63.60% of the companies in the same industry.
Industry RankSector Rank
ROA 2.87%
ROE 2.93%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
XXI Yearly ROA, ROE, ROICXXI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 50 100 150

1.3 Margins

  • XXI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XXI Yearly Profit, Operating, Gross MarginsXXI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XXI Health Analysis

2.1 Basic Checks

  • XXI has about the same amout of shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, XXI has about the same debt to assets ratio.
XXI Yearly Shares OutstandingXXI Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M 10M
XXI Yearly Total Debt VS Total AssetsXXI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • XXI has an Altman-Z score of 1238.74. This indicates that XXI is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of XXI (1238.74) is better than 100.00% of its industry peers.
  • XXI has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • XXI's Debt to Equity ratio of 0.01 is amongst the best of the industry. XXI outperforms 84.94% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1238.74
ROIC/WACCN/A
WACCN/A
XXI Yearly LT Debt VS Equity VS FCFXXI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • XXI has a Current Ratio of 0.13. This is a bad value and indicates that XXI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • XXI has a worse Current ratio (0.13) than 92.05% of its industry peers.
  • XXI has a Quick Ratio of 0.13. This is a bad value and indicates that XXI is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of XXI (0.13) is worse than 92.05% of its industry peers.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
XXI Yearly Current Assets VS Current LiabilitesXXI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100K 200K 300K 400K

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. XXI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 1309.11% over the past year.
EPS 1Y (TTM)1309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocksShow best growing peers

1

4. XXI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 12.96 indicates a correct valuation of XXI.
  • The rest of the industry has a similar Price/Earnings ratio as XXI.
  • XXI is valuated cheaply when we compare the Price/Earnings ratio to 26.21, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.96
Fwd PE N/A
XXI Price Earnings VS Forward Price EarningsXXI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XXI Per share dataXXI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XXI Dividend Analysis

5.1 Amount

  • XXI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XXI Fundamentals: All Metrics, Ratios and Statistics

TWENTY ONE CAPITAL INC-CL A

NYSE:XXI (4/7/2026, 3:05:55 PM)

6.22

-0.17 (-2.66%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners32.18%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.05B
Revenue(TTM)N/A
Net Income(TTM)3.08M
AnalystsN/A
Price TargetN/A
Short Float %8.98%
Short Ratio2.39
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 12.96
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 38.55
P/tB 38.55
EV/EBITDA N/A
EPS(TTM)0.48
EY7.72%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.16
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.32
Profitability
Industry RankSector Rank
ROA 2.87%
ROE 2.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 1238.74
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1309.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

TWENTY ONE CAPITAL INC-CL A / XXI Fundamental Analysis FAQ

What is the fundamental rating for XXI stock?

ChartMill assigns a fundamental rating of 2 / 10 to XXI.


Can you provide the valuation status for TWENTY ONE CAPITAL INC-CL A?

ChartMill assigns a valuation rating of 1 / 10 to TWENTY ONE CAPITAL INC-CL A (XXI). This can be considered as Overvalued.


How profitable is TWENTY ONE CAPITAL INC-CL A (XXI) stock?

TWENTY ONE CAPITAL INC-CL A (XXI) has a profitability rating of 1 / 10.


How financially healthy is TWENTY ONE CAPITAL INC-CL A?

The financial health rating of TWENTY ONE CAPITAL INC-CL A (XXI) is 3 / 10.